Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
DOI:
https://doi.org/10.2340/1651-226X.2025.43167Keywords:
Stomach neoplasms, oesophageal neoplasms, neoadjuvant therapy, retrospective study, epidemiology, survival analysisAbstract
Background and purpose: Gastroesophageal cancers are highly prevalent internationally, with many patients diagnosed with metastatic disease, leading to challenging treatment and poor survival. This study uses real-world evidence from a population-level database to describe demographics, clinical characteristics, initial treatment patterns, and survival for patients with gastroesophageal cancer in Norway.
Material and methods: Individual patient data was sourced from the Cancer Registry of Norway for patients diagnosed with oesophageal squamous cell carcinoma (ESCC), oesophageal adenocarcinoma (EAC), gastroesophageal junction cancer (GEJC), and gastric cancer from 2001 to 2021, with follow-up from diagnosis to death or last follow-up. Treatment patterns were captured from 2010 to 2022, defined as curative or palliative based on surgery, chemotherapy, and radiotherapy.
Results and interpretation: The cohort included 14,334 Norwegian patients with gastroesophageal cancer; predominantly male, mean age 69–73 years, with a median follow-up of 9–11 months across cancer subtypes. Approximately 40% of patients received curative treatment, and multi-modality treatments increased for EAC, GEJC, and ESCC. Median survival ranged from 6 to 11 months for patients treated palliatively, and 17–95 months for those treated with curative intent. Interestingly, median survival was higher for patients with EAC and GEJC treated with neoadjuvant chemotherapy (86.1 and 75.1 months) versus neoadjuvant chemoradiotherapy (49.1 and 42.1 months), which was confirmed by a multivariate Cox regression model adjusted for age, sex, and disease stage.
This study demonstrates that multimodal treatment strategies, consisting of chemotherapy and surgery, may be associated with improved survival outcomes for gastroesophageal cancers. Future studies are required to identify optimum treatment strategies for gastroesophageal cancer subtypes.
Downloads
References
Cancer Registry of Norway Cancer in Norway 2023: Cancer incidence, mortality, survival and prevalence in Norway. 2024. Updated: 07/05/2024 [cited: 27/03/2024] Available from: https://www.kreftregisteret.no/en/Key-figures-on-cancer/key-figures-on-cancer/
Cancer Registry of Norway. Cancer of the esophagus and stomach [Internet]. 2024 [updated 2023 Aug 14; cited 2024 Mar 27]. Available from: https://www.kreftregisteret.no/en/Cancers/cancer-of-the-esophagus-and-stomach/
Cancer Registry of Norway Annual report. 2016: results and improvement measures from the national quality register for esophageal- and ventricular cancer. 2016. [Cited: 27/03/2024] Available from: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_spiseror-og-magesekkreft.pdf
Franck C, Zimmermann N, Goni E, Lippert H, Ridwelski K, Kruschewski M, et al. Different prevalence of alarm, dyspeptic and reflux symptoms in patients with cardia and non-cardia gastric cancer. J Gastrointestin Liver Dis. 2021;30(4):431–7.
https://doi.org/10.15403/jgld-3795 DOI: https://doi.org/10.15403/jgld-3795
Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic advances in the treatment of gastroesophageal cancers. Biomolecules. 2023;13(5):796.
https://doi.org/10.3390/biom13050796 DOI: https://doi.org/10.3390/biom13050796
National Institute of Health and Care Excellence Oesophago-gastric cancer: assessment and management in adults. NICE guideline [NG83]. 2018. Updated 04/07/2023. [Cited: 27/03/2024] Available from: https://www.nice.org.uk/guidance/ng83
Hemminki K, Tichanek F, Försti A, Hemminki O, Hemminki A. Survival in gastric and esophageal cancers in the Nordic countries through a half century. Cancer Med 2023;12(9):10212–21.
https://doi.org/10.1002/cam4.5748 DOI: https://doi.org/10.1002/cam4.5748
Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–15.
https://doi.org/10.1016/j.asjsur.2016.10.005 DOI: https://doi.org/10.1016/j.asjsur.2016.10.005
Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.
https://doi.org/10.1016/S0140-6736(18)32557-1 DOI: https://doi.org/10.1016/S0140-6736(18)32557-1
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
https://doi.org/10.1056/NEJMoa055531 DOI: https://doi.org/10.1056/NEJMoa055531
Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995–2004.
https://doi.org/10.1200/JCO.20.03614 DOI: https://doi.org/10.1200/JCO.20.03614
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
https://doi.org/10.1056/NEJMoa1112088 DOI: https://doi.org/10.1056/NEJMoa1112088
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20.
https://doi.org/10.1016/j.annonc.2022.07.004 DOI: https://doi.org/10.1016/j.annonc.2022.07.004
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992–1004.
https://doi.org/10.1016/j.annonc.2022.07.003 DOI: https://doi.org/10.1016/j.annonc.2022.07.003
Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323–35.
https://doi.org/10.1056/NEJMoa2409408 DOI: https://doi.org/10.1056/NEJMoa2409408
Cancer Registry of Norway. 2024 [updated 2023 Aug 14; cited 2024 Mar 27]. Available from: https://www.kreftregisteret.no/en/
Engeland A, Nystad W, Selmer R. The Cancer Registry of Norway – ‘a ground for scientific harvesting’. Norsk Epidemiol. 2022;30(1–2):
101–5.
https://doi.org/10.5324/nje.v30i1-2.4985 DOI: https://doi.org/10.5324/nje.v30i1-2.4985
Norwegian Patient Registry (NPR). 2024 [updated 2023 Aug 14; cited 2024 Mar 27]. Available from: https://helsedata.no/en/forvaltere/norwegian-institute-of-public-health/norwegian-patient-registry-npr/
Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian Patient Registry and the Norwegian Registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55.
https://doi.org/10.1177/1403494819859737 DOI: https://doi.org/10.1177/1403494819859737
Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.
https://doi.org/10.1016/S1470-2045(18)30132-3 DOI: https://doi.org/10.1016/S1470-2045(18)30132-3
Cai Y, Lin J, Wei W, Chen P, Yao K. Burden of esophageal cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Public Health. 2022;10:952087.
https://doi.org/10.3389/fpubh.2022.952087 DOI: https://doi.org/10.3389/fpubh.2022.952087
Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47:101404.
https://doi.org/10.1016/j.eclinm.2022.101404 DOI: https://doi.org/10.1016/j.eclinm.2022.101404
Stabellini N, Chandar AK, Chak A, Barda AJ, Dmukauskas M, Waite K, et al. Sex differences in esophageal cancer overall and by histological subtype. Sci Rep. 2022;12(1):5248.
https://doi.org/10.1038/s41598-022-09193-x DOI: https://doi.org/10.1038/s41598-022-09193-x
Guan W-L, He Y, Xu R-H. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.
https://doi.org/10.1186/s13045-023-01451-3 DOI: https://doi.org/10.1186/s13045-023-01451-3
Kalff MC, van Berge Henegouwen MI, Baas PC, Bahadoer RR, Belt EJT, Brattinga B, et al. Trends in distal esophageal and gastroesophageal junction cancer care: the Dutch nationwide Ivory study. Ann Surg. 2023;277(4):619–28.
https://doi.org/10.1097/SLA.0000000000005292 DOI: https://doi.org/10.1097/SLA.0000000000005292
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.
https://doi.org/10.1002/14651858.CD004064.pub4 DOI: https://doi.org/10.1002/14651858.CD004064.pub4
Jeon WJ, Park D, Al-Manaseer F, Chen Y-J, Kim JY, Liu B, et al. Survival and treatment patterns in stage II to III esophageal cancer. JAMA Netw Open. 2024;7(10):e2440568.
https://doi.org/10.1001/jamanetworkopen.2024.40568 DOI: https://doi.org/10.1001/jamanetworkopen.2024.40568
Reynolds JV, Preston SR, O’Neill B, Lowery MA, Baeksgaard L, Crosby T, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015–27.
https://doi.org/10.1016/S2468-1253(23)00243-1 DOI: https://doi.org/10.1016/S2468-1253(23)00243-1
Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.
https://doi.org/10.1016/S1470-2045(15)00040-6 DOI: https://doi.org/10.1016/S1470-2045(15)00040-6
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.
https://doi.org/10.1056/NEJMoa2032125 DOI: https://doi.org/10.1056/NEJMoa2032125
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Alexander Kolstad, Gabrielle Emanuel, Geir Olav Hjortland, Yngvar Nilssen, Maria Ulvestad, Ali Areffard, Eirik Kjus Aahlin
This work is licensed under a Creative Commons Attribution 4.0 International License.
